Rural issues
The AHA Rural Health Care Leadership Conference, Feb. 2-5 in Phoenix, offers an unparalleled opportunity to learn and share with renowned health care leaders innovating at the forefront of change, writes AHA Executive Vice President Maryjane Wurth.
Preserving rural health and advancing health in America go hand-in-hand.
The House Ways and Means Committee today requested input on priority topics for its Rural and Underserved Communities Health Task Force to consider as it works to improve care delivery and health outcomes in these communities.
Potentially preventable deaths from cancer, heart disease, unintentional injury, chronic lower respiratory disease and stroke were more common in rural than urban counties between 2010 and 2017.
AHA thanks Senators Cortez Masto and Roberts for introducing legislation that fixes a formula to measure accountable care organization (ACO) performance by more fairly comparing ACOs to their markets. Specifically, S.2648, the Rural ACO Improvement Act, amends title XVIII of the Social…
AHA's input on the Health Resources and Services Administration’s Rural Access to Health Care Services request for information (RFI). The RFI solicits comments on access to care in rural areas.
The AHA today submitted recommendations to the Health Resources and Services Administration in response to the agency’s Rural Access to Health Care Services Request for Information.
The American Hospital Association’s 2020 Rural Health Care Leadership Conference, February 2-5, Phoenix, AZ, b brings together top practitioners and thinkers to share strategies and resources for accelerating the shift to a more integrated and sustainable rural health system. We’ll examine the most…
CMS’ proposal mandating the disclosure of negotiated charges between health plans and hospitals is the wrong approach, exceeds the Administration's legal authority and should be abandoned, AHA told the agency today.
The AHA today expressed support for the Closing Loopholes for Orphan Drugs Act, H.R. 4538, bipartisan legislation that would limit the “orphan drug” exclusion for 340B Drug Pricing Program rural and cancer hospitals.